Reuters: Sanofi mulls nominees for Genzyme board

Suggesting that Sanofi-Aventis is prepping for a possible proxy fight at Genzyme, the French drugmaker has hired a search firm to vet for potential candidates to nominate to Genzyme's board, sources tell Reuters. Report

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.